Seth Wander, MD, PhD

Seth Wander, MD, PhD, discusses how he approaches therapeutic treatment for patients with ER+ advanced breast cancer in the clinic.

Seth Wander, MD, PhD, discusses the present limitations of first- and later-line therapy for HR+ metastatic breast cancer.

Seth Wander, MD, PhD, discusses the ELAINE-1, ELAINE-2, and ELAINE-3 trials in patients with ER-positive, HER2-negative metastatic breast cancer.

Seth Wander, MD, PhD, discusses findings from an analysis of baseline genomic alterations in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who were enrolled in the single-arm, phase 2 ELAINE-2 trial of lasofoxifene plus abemaciclib.

Seth Wander, MD, PhD, discusses the evaluation of vepdegestrant (ARV-471), a proteolysis targeting chimera estrogen receptor degrader, in patients with advanced estrogen receptor/HER2-negative breast cancer.

Seth Wander, MD, PhD, discusses challenges related to the ongoing platinum chemotherapy shortage for patients with breast cancer and other malignancies, as well as ways that oncologists and cancer centers can operate during the shortage to continue to provide appropriate care for patients.

Seth Wander, MD, PhD, discusses the investigation of resistance to CDK4/6 inhibitors and the role of NF1 mutations in breast cancer.